Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Winter Respiratory Infections Linked to Vitamin D Levels

By BiotechDaily International staff writers
Posted on 30 Jun 2010
Print article
The increased incidence of influenza and other viral respiratory tract infections during the winter months may be linked to decreased levels of vitamin D.

Investigators at the Yale University School of Medicine (New Haven, CT, USA) determined serial monthly concentrations of 25-hydroxyvitamin D during the fall and winter 2009–2010 in 198 healthy adults, who did not know which serum components were being measured. The participants were evaluated for the development of any acute respiratory tract infections by investigators who did not know the patients' 25-hydroxyvitamin D concentrations.

Results published in the June 14, 2010, online edition of the journal PloS ONE revealed that 18 participants maintained vitamin D levels of 38 ng/mL or higher during the study period. Of this group only three (16.6 %) developed viral infections. Of the 180 other participants, 81 (45 %) developed viral infections. Those with the higher vitamin D levels also experienced a marked reduction in the number of days required to recover from their respiratory infections.

The investigators concluded that, "Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/mL or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones. The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza.”

Related Links:

Yale University School of Medicine




Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.